secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2022-12-06T23:59:59+00:00
Accession:  0001599298-22-000136
Event type: other_material
Sentiment:  positive
Materiality: 0.95
Item codes: 1.01, 8.01, 2.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics Signs $5B License Deal with Akeso for Bispecific Antibody Ivonescimab
--------------------------------------------------------------------------------

- Summit pays Akeso $500M upfront ($300M due after HSR clearance, $200M within 90 days) plus up to $4.5B milestones for ivonescimab rights in US, Canada, Europe, Japan.
- Robert Duggan and Maky Zanganeh lend Summit $520M via unsecured promissory notes at 7.5% interest maturing Feb and Sept 2023, extendable to Sept 2024.
- Summit board approves $500M rights offering to stockholders with subscription price at lesser of $1.05 or 5-day VWAP; Duggan and Zanganeh intend to participate.
- Dr. Michelle Xia, co-founder and CEO of Akeso, appointed to Summit's board effective upon antitrust clearance.
- Summit plans to start clinical studies for SMT112 (ivonescimab) by Q2 2023, initially in non-small cell lung cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929822000136/0001599298-22-000136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929822000136/smmt-20221205.htm
  HTML page:      https://secwatch.observer/filing/0001599298-22-000136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer